Incidence, surveillance and natural history of high‐grade prostatic epithelial neoplasia in the era of multiparametric MRI and targeted biopsy

IF 3.7 2区 医学 Q1 UROLOGY & NEPHROLOGY
Nathalie Eid, Herbert Lepor
{"title":"Incidence, surveillance and natural history of high‐grade prostatic epithelial neoplasia in the era of multiparametric MRI and targeted biopsy","authors":"Nathalie Eid, Herbert Lepor","doi":"10.1111/bju.16748","DOIUrl":null,"url":null,"abstract":"ObjectivesTo determine the incidence of isolated high grade prostatic epithelial neoplasia (iHGPIN) following magnetic resonance imaging (MRI)–ultrasonography co‐registration fusion targeted biopsy (MRFTB) coupled with systematic biopsy (SB) and to assess the detection rates of clinically significant prostate cancer (csPCa).Patients and MethodsBeginning in June 2012, most patients at our institution underwent multiparametric MRI (mpMRI) before prostate biopsy. Biopsies were performed between June 2012 and October 2021. The surveillance protocol for iHGPIN included prostate‐specific antigen assessment every 6 months, digital rectal examinations annually, and multiparametric MRI (mpMRI) at 3 years. Repeat biopsies were recommended primarily for suspicious mpMRI, defined as a new Prostate Imaging‐Reporting and Data System (PI‐RADS) score >2 region of interest (ROI) or an increase in size of the pre‐existing ROI.ResultsOf the 628 biopsies, 230 (33.7%), 48 (7.0%), 404 (59.2%) were interpreted as benign, iHGPIN, or prostate cancer (PCa), respectively. Of these cancers 140 (34.7%) and 264 (65.3%) were low‐risk PCa and csPCa, respectively. iHGPIN was detected in MRRFTB only, SB only, and both MRFRB + SB in six (12.5%) 36 (75%), and six patients (12.5%), respectively. Of the 32 MRI scans performed at 3 years, a new PI‐RADS score >2 ROI or an increase in the size or PI‐RADS score of a pre‐existing ROI was observed in four and eight patients, respectively. Nine of these underwent biopsy. Three additional biopsies were performed on non‐suspicious mpMRI. csPCa was detected in two patients, both with an enlarging ROI.ConclusionTo our knowledge, this is the first study examining the incidence, natural history, and subsequent csPCa detection rates for iHGPIN in the era of mpMRI and MRI targeted biopsy. The lower prevalence of iHGPIN is attributed to the selection of biopsy candidates based on mpMRI and an increased likelihood of detecting pre‐existing csPCa. Our findings provide compelling evidence that biopsy strategies limited to MRI targets will almost eliminate iHGPIN detection while decreasing detection of csPCa. A 3‐year biopsy should be performed only in men with suspicious mpMRI.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"254 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJU International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bju.16748","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

ObjectivesTo determine the incidence of isolated high grade prostatic epithelial neoplasia (iHGPIN) following magnetic resonance imaging (MRI)–ultrasonography co‐registration fusion targeted biopsy (MRFTB) coupled with systematic biopsy (SB) and to assess the detection rates of clinically significant prostate cancer (csPCa).Patients and MethodsBeginning in June 2012, most patients at our institution underwent multiparametric MRI (mpMRI) before prostate biopsy. Biopsies were performed between June 2012 and October 2021. The surveillance protocol for iHGPIN included prostate‐specific antigen assessment every 6 months, digital rectal examinations annually, and multiparametric MRI (mpMRI) at 3 years. Repeat biopsies were recommended primarily for suspicious mpMRI, defined as a new Prostate Imaging‐Reporting and Data System (PI‐RADS) score >2 region of interest (ROI) or an increase in size of the pre‐existing ROI.ResultsOf the 628 biopsies, 230 (33.7%), 48 (7.0%), 404 (59.2%) were interpreted as benign, iHGPIN, or prostate cancer (PCa), respectively. Of these cancers 140 (34.7%) and 264 (65.3%) were low‐risk PCa and csPCa, respectively. iHGPIN was detected in MRRFTB only, SB only, and both MRFRB + SB in six (12.5%) 36 (75%), and six patients (12.5%), respectively. Of the 32 MRI scans performed at 3 years, a new PI‐RADS score >2 ROI or an increase in the size or PI‐RADS score of a pre‐existing ROI was observed in four and eight patients, respectively. Nine of these underwent biopsy. Three additional biopsies were performed on non‐suspicious mpMRI. csPCa was detected in two patients, both with an enlarging ROI.ConclusionTo our knowledge, this is the first study examining the incidence, natural history, and subsequent csPCa detection rates for iHGPIN in the era of mpMRI and MRI targeted biopsy. The lower prevalence of iHGPIN is attributed to the selection of biopsy candidates based on mpMRI and an increased likelihood of detecting pre‐existing csPCa. Our findings provide compelling evidence that biopsy strategies limited to MRI targets will almost eliminate iHGPIN detection while decreasing detection of csPCa. A 3‐year biopsy should be performed only in men with suspicious mpMRI.
在多参数MRI和靶向活检时代,高级别前列腺上皮瘤的发病率、监测和自然病史
目的探讨磁共振成像(MRI) -超声共登记融合靶向活检(MRFTB)联合系统活检(SB)后孤立性高级别前列腺上皮瘤变(iHGPIN)的发生率,并评估临床显著性前列腺癌(csPCa)的检出率。患者和方法从2012年6月开始,我院大多数患者在前列腺活检前接受了多参数MRI (mpMRI)检查。活组织检查于2012年6月至2021年10月期间进行。iHGPIN的监测方案包括每6个月进行前列腺特异性抗原评估,每年进行直肠指检,每3年进行多参数MRI (mpMRI)检查。建议对可疑的mpMRI进行重复活检,定义为新的前列腺成像报告和数据系统(PI - RADS)评分>;2感兴趣区域(ROI)或先前存在的ROI大小增加。结果628例活检中,分别有230例(33.7%)、48例(7.0%)、404例(59.2%)为良性、iHGPIN或前列腺癌(PCa)。在这些癌症中,140例(34.7%)和264例(65.3%)分别为低风险PCa和csPCa。iHGPIN分别在6例(12.5%)、36例(75%)和6例(12.5%)的MRRFTB、SB和MRFRB + SB患者中检测到。在3年内进行的32次MRI扫描中,分别在4例和8例患者中观察到新的PI - RADS评分为2 ROI或先前存在的ROI的大小或PI - RADS评分增加。其中9例进行了活检。另外进行了三次非可疑mpMRI活检。在2例患者中检测到csPCa,均伴有ROI增大。据我们所知,这是在mpMRI和MRI靶向活检时代首次研究iHGPIN的发病率、自然病史和随后的csPCa检出率。iHGPIN患病率较低的原因是基于mpMRI选择活检候选者,以及检测先前存在的csPCa的可能性增加。我们的研究结果提供了令人信服的证据,表明局限于MRI目标的活检策略几乎可以消除iHGPIN检测,同时减少csPCa的检测。只有在mpMRI可疑的男性中,才应进行3年活检。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BJU International
BJU International 医学-泌尿学与肾脏学
CiteScore
9.10
自引率
4.40%
发文量
262
审稿时长
1 months
期刊介绍: BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信